Ocugen (OCGN) Projected to Post Earnings on Tuesday

Ocugen (NASDAQ:OCGN) is anticipated to post its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Ocugen to post earnings of ($0.05) per share and revenue of $0.4180 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). The firm had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.86 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Stock Up 4.2%

Shares of Ocugen stock traded up $0.08 during trading hours on Monday, hitting $1.88. 859,603 shares of the company’s stock traded hands, compared to its average volume of 7,324,294. Ocugen has a twelve month low of $0.64 and a twelve month high of $2.73. The company has a market cap of $634.73 million, a PE ratio of -8.20 and a beta of 2.30. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 8.04. The stock has a 50 day simple moving average of $1.88 and a 200-day simple moving average of $1.59.

Institutional Investors Weigh In On Ocugen

A number of institutional investors have recently made changes to their positions in OCGN. Virtu Financial LLC bought a new position in Ocugen during the fourth quarter worth $106,000. NewEdge Advisors LLC lifted its stake in Ocugen by 69.0% during the fourth quarter. NewEdge Advisors LLC now owns 135,460 shares of the company’s stock worth $183,000 after purchasing an additional 55,305 shares during the last quarter. Millennium Management LLC lifted its stake in Ocugen by 29.7% during the fourth quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock worth $7,285,000 after purchasing an additional 1,234,268 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in Ocugen during the fourth quarter worth $196,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in Ocugen during the fourth quarter worth $38,000. 10.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on OCGN shares. Weiss Ratings restated a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Oppenheimer started coverage on Ocugen in a research note on Wednesday, March 11th. They set an “outperform” rating and a $10.00 target price for the company. Canaccord Genuity Group began coverage on shares of Ocugen in a research report on Tuesday, March 17th. They set a “buy” rating and a $12.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Ocugen in a report on Wednesday, March 25th. Finally, HC Wainwright increased their price objective on shares of Ocugen from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.75.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.